Jeffrey S. Miller, MD, University of Minnesota, Minneapolis, MN, discusses the mechanism of action and rationale behind the development of GTB-3550, a tri-specific killer engager (TriKE®) for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.